{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:15:22Z","timestamp":1790007322596,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objective of this study was to investigate the trends and prescribing patterns of antimigraine medicines in China.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The prescription data of outpatients diagnosed with migraine between 2018 and 2022 were extracted from the Hospital Prescription Analysis Cooperative Project of China. The demographic characteristics of migraine patients, prescription trends, and corresponding expenditures on antimigraine medicines were analyzed. We also investigated prescribing patterns of combination therapy and medicine overuse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 32,246 outpatients who were diagnosed with migraine at 103 hospitals were included in this study. There were no significant trend changes in total outpatient visits, migraine prescriptions, or corresponding expenditures during the study period. Of the patients who were prescribed therapeutic medicines, 70.23% received analgesics, and 26.41% received migraine-specific agents. Nonsteroidal anti-inflammatory drugs (NSAIDs; 28.03%), caffeine-containing agents (22.15%), and opioids (16.00%) were the most commonly prescribed analgesics, with corresponding cost proportions of 11.35%, 4.08%, and 19.61%, respectively. Oral triptans (26.12%) were the most commonly prescribed migraine-specific agents and accounted for 62.21% of the total therapeutic expenditures. The proportion of patients receiving analgesic prescriptions increased from 65.25% in 2018 to 75.68% in 2022, and the proportion of patients receiving concomitant triptans decreased from 29.54% in 2018 to 21.55% in 2022 (both <jats:italic>P\u2009&lt;\u2009\u00a00.001<\/jats:italic>). The most frequently prescribed preventive medication classes were calcium channel blockers (CCBs; 51.59%), followed by antidepressants (20.59%) and anticonvulsants (15.82%), which accounted for 21.90%, 34.18%, and 24.15%, respectively, of the total preventive expenditures. Flunarizine (51.41%) was the most commonly prescribed preventive drug. Flupentixol\/melitracen (7.53%) was the most commonly prescribed antidepressant. The most commonly prescribed anticonvulsant was topiramate (9.33%), which increased from 6.26% to 12.75% (both <jats:italic>P\u2009&lt;\u2009\u00a00.001<\/jats:italic>). A total of 3.88% of the patients received combined therapy for acute migraine treatment, and 18.63% received combined therapy for prevention. The prescriptions for 69.21% of opioids, 38.53% of caffeine-containing agents, 26.61% of NSAIDs, 13.97% of acetaminophen, and 6.03% of triptans were considered written medicine overuse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Migraine treatment gradually converges toward evidence-based and guideline-recommended treatment. Attention should be given to opioid prescribing, weak evidence-based antidepressant use, and medication overuse in migraine treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01775-6","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T11:02:09Z","timestamp":1713870129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jing","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"1775_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-017-0758-6","volume":"18","author":"L Huang","year":"2017","unstructured":"Huang L, Juan Dong H, Wang X, Wang Y, Xiao Z (2017) Duration and frequency of migraines affect cognitive function: evidence from neuropsychological tests and event-related potentials. J Headache Pain 18:54","journal-title":"J Headache Pain"},{"key":"1775_CR2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Ozge A et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495","journal-title":"Lancet"},{"key":"1775_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"Collaborators GBDH","year":"2018","unstructured":"Collaborators GBDH (2018) Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 17:954\u2013976","journal-title":"Lancet Neurol"},{"key":"1775_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"Collaborators GBDN","year":"2019","unstructured":"Collaborators GBDN (2019) Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 18:459\u2013480","journal-title":"Lancet Neurol"},{"key":"1775_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s10194-024-01712-7","volume":"25","author":"C Tana","year":"2024","unstructured":"Tana C, Raffaelli B, Souza MNP, de la Torre ER, Massi DG, Kisani N et al (2024) Health equity, care access and quality in headache - part 1. J Headache Pain 25:12","journal-title":"J Headache Pain"},{"key":"1775_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5847\/wjem.j.1920-8642.2017.03.002","volume":"8","author":"E Shao","year":"2017","unstructured":"Shao E, Hughes J, Eley R (2017) The presenting and prescribing patterns of migraine in an Australian emergency department: a descriptive exploratory study. World J Emerg Med 8:170\u2013176","journal-title":"World J Emerg Med"},{"key":"1775_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11096-015-0089-0","volume":"37","author":"I Truter","year":"2015","unstructured":"Truter I (2015) Prescribing patterns of anti-migraine medicines in South Africa using a claims database. Int J Clin Pharm 37:447\u2013451","journal-title":"Int J Clin Pharm"},{"key":"1775_CR8","doi-asserted-by":"publisher","first-page":"e059926","DOI":"10.1136\/bmjopen-2021-059926","volume":"13","author":"S Lee","year":"2023","unstructured":"Lee S, Yeo J, Lee SH, Lee YJ, Lee S, Ha IH (2023) Trends in healthcare utilisation of patients with migraine in South Korea: a retrospective observational study using Health Insurance Review and Assessment Service National Patient Sample data from 2010 to 2018. BMJ Open 13:e059926","journal-title":"BMJ Open"},{"key":"1775_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s10194-023-01699-7","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Rubio-Beltran E, Cho SJ, De Icco R, Labastida-Ramirez A, Onan D et al (2023) Health equity, care access and quality in headache - part 2. J Headache Pain 24:167","journal-title":"J Headache Pain"},{"key":"1775_CR10","doi-asserted-by":"publisher","first-page":"915823","DOI":"10.3389\/fpsyt.2022.915823","volume":"13","author":"G Lou","year":"2022","unstructured":"Lou G, Yu Z, Chen L, Zhou Y, Zhang L (2022) Trends in prescriptions for insomnia in a province in China between 2015 and 2019. Front Psychiatry 13:915823","journal-title":"Front Psychiatry"},{"key":"1775_CR11","doi-asserted-by":"publisher","first-page":"649589","DOI":"10.3389\/fneur.2021.649589","volume":"12","author":"L Yu","year":"2021","unstructured":"Yu L, Zhu W, Zhu X, Lu Y, Yu Z, Dai H (2021) Anti-seizure medication prescription in adult outpatients with epilepsy in China, 2013-2018. Front Neurol 12:649589","journal-title":"Front Neurol"},{"key":"1775_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/YIC.0000000000000278","volume":"34","author":"L Yu","year":"2019","unstructured":"Yu L, Chen X, Yu Z (2019) Trends of antidementia drugs use in outpatients with Alzheimer\u2019s disease in six major cities of China: 2012-2017. Int Clin Psychopharmacol 34:312\u2013316","journal-title":"Int Clin Psychopharmacol"},{"key":"1775_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V et al (2019) Aids to management of headache disorders in primary care (2nd edition)\u202f: on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain 20:57","journal-title":"J Headache Pain"},{"key":"1775_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17:501\u2013514","journal-title":"Nat Rev Neurol"},{"key":"1775_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"MJ Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 55:3\u201320","journal-title":"Headache"},{"key":"1775_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Society HCCotIH","year":"2018","unstructured":"Society HCCotIH (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"key":"1775_CR17","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1212\/WNL.0000000000009324","volume":"95","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Buse DC, Friedman BW, Feder L, Adams AM, Fanning KM et al (2020) Characterizing opioid use in a US population with migraine: results from the CaMEO study. Neurology 95:e457\u2013e468","journal-title":"Neurology"},{"key":"1775_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11916-016-0581-9","volume":"20","author":"MT Stone","year":"2016","unstructured":"Stone MT, Weed V, Kulich RJ (2016) Opioid treatment of migraine: risk factors and behavioral issues. Curr Pain Headache Rep 20:51","journal-title":"Curr Pain Headache Rep"},{"key":"1775_CR19","doi-asserted-by":"crossref","first-page":"333102423117416","DOI":"10.1177\/03331024231174160","volume":"43","author":"RF van Welie","year":"2023","unstructured":"van Welie RF, van Welie FC, de Vries LS, Dahan A, van Velzen M, Terwindt GM (2023) Characterizing opioid use in a Dutch cohort with migraine. Cephalalgia 43:3331024231174160","journal-title":"Cephalalgia"},{"key":"1775_CR20","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/head.14217","volume":"61","author":"RAF Pellatt","year":"2021","unstructured":"Pellatt RAF, Kamona S, Chu K, Sweeny A, Kuan WS, Kinnear FB et al (2021) The headache in emergency departments study: opioid prescribing in patients presenting with headache. A multicenter, cross-sectional, observational study. Headache 61:1387\u20131402","journal-title":"Headache"},{"key":"1775_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/13696998.2019.1590841","volume":"22","author":"A Donnet","year":"2019","unstructured":"Donnet A, Emery C, Aly S, Allaf B, Cayre F, Mahieu N et al (2019) Migraine burden and costs in France: a nationwide claims database analysis of triptan users. J Med Econ 22:616\u2013624","journal-title":"J Med Econ"},{"key":"1775_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S, Zhang Y, Yao Y, Cao H (2020) Migraine treatment and healthcare costs: retrospective analysis of the China health insurance research association (CHIRA) database. J Headache Pain 21:53","journal-title":"J Headache Pain"},{"key":"1775_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-023-01657-3","volume":"24","author":"CI Deligianni","year":"2023","unstructured":"Deligianni CI, Sacco S, Ekizoglu E, Uluduz D, Gil-Gouveia R, MaassenVanDenBrink A et al (2023) European headache federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine. J Headache Pain 24:128","journal-title":"J Headache Pain"},{"key":"1775_CR24","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/j.pain.0000000000001456","volume":"160","author":"A Stubberud","year":"2019","unstructured":"Stubberud A, Flaaen NM, McCrory DC, Pedersen SA, Linde M (2019) Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain 160:762\u2013772","journal-title":"Pain"},{"key":"1775_CR25","first-page":"CD010610","volume":"2013","author":"M Linde","year":"2013","unstructured":"Linde M, Mulleners WM, Chronicle EP, McCrory DC (2013) Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013:CD010610","journal-title":"Cochrane Database Syst Rev"},{"key":"1775_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s10194-023-01671-5","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Garcia-Azorin D, Boucherie DM, Amin FM, Deligianni CI, Gil-Gouveia R et al (2023) European headache federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention - part 3: topiramate. J Headache Pain 24:134","journal-title":"J Headache Pain"},{"key":"1775_CR27","doi-asserted-by":"publisher","first-page":"e2290","DOI":"10.1002\/brb3.2290","volume":"11","author":"C Hu","year":"2021","unstructured":"Hu C, Zhang Y, Tan G (2021) Advances in topiramate as prophylactic treatment for migraine. Brain Behav 11:e2290","journal-title":"Brain Behav"},{"key":"1775_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-023-00438-z","volume":"12","author":"E Bentivegna","year":"2023","unstructured":"Bentivegna E, Onan D, Martelletti P (2023) Unmet needs in preventive treatment of migraine. Neurol Ther 12:337\u2013342","journal-title":"Neurol Ther"},{"key":"1775_CR29","doi-asserted-by":"publisher","first-page":"e6989","DOI":"10.1097\/MD.0000000000006989","volume":"96","author":"XM Xu","year":"2017","unstructured":"Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD (2017) Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore) 96:e6989","journal-title":"Medicine (Baltimore)"},{"key":"1775_CR30","doi-asserted-by":"publisher","first-page":"107151","DOI":"10.1016\/j.clineuro.2022.107151","volume":"214","author":"M Hedayat","year":"2022","unstructured":"Hedayat M, Nazarbaghi S, Heidari M, Sharifi H (2022) Venlafaxine can reduce the migraine attacks as well as amitriptyline: a noninferiority randomized trial. Clin Neurol Neurosurg 214:107151","journal-title":"Clin Neurol Neurosurg"},{"key":"1775_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4103\/0253-7613.186192","volume":"48","author":"MS Solanki","year":"2016","unstructured":"Solanki MS, Banwari G (2016) Irrational fixed dose combinations of psychotropic drugs in India: cause of concern. Indian J Pharmacol 48:468\u2013469","journal-title":"Indian J Pharmacol"},{"key":"1775_CR32","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","volume":"2","author":"A Singh","year":"2020","unstructured":"Singh A, Gupta D, Sahoo AK (2020) Acute migraine: can the new drugs clinically outpace? SN Compr Clin Med 2:1132\u20131138","journal-title":"SN Compr Clin Med"},{"key":"1775_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14656566.2017.1288721","volume":"18","author":"AE Macone","year":"2017","unstructured":"Macone AE, Perloff MD (2017) Triptans and migraine: advances in use, administration, formulation, and development. Expert Opin Pharmacother 18:387\u2013397","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 4","key":"1775_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A et al (2015) Triptans in the acute treatment of migraine: a systematic review and network Meta-analysis. Headache 55(Suppl 4):221\u2013235","journal-title":"Headache"},{"key":"1775_CR35","doi-asserted-by":"publisher","first-page":"e2689","DOI":"10.1002\/brb3.2689","volume":"12","author":"J Zhu","year":"2022","unstructured":"Zhu J, Chen J, Zhang K (2022) Clinical effect of flunarizine combined with duloxetine in the treatment of chronic migraine comorbidity of depression and anxiety disorder. Brain Behav 12:e2689","journal-title":"Brain Behav"},{"key":"1775_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C et al (2023) Medication overuse headache. Nat Rev Dis Primers 9:5","journal-title":"Nat Rev Dis Primers"},{"key":"1775_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/CPJ.0000000000001037","volume":"11","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Buse DC, Argoff CE, Reed ML, Fanning KM, Hussar CR et al (2021) Medication overuse and headache burden: results from the CaMEO study. Neurol Clin Pract 11:216\u2013226","journal-title":"Neurol Clin Pract"},{"key":"1775_CR38","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1007\/s42399-020-00424-8","volume":"2","author":"MV L\u00f3pez Mart\u00ednez","year":"2020","unstructured":"L\u00f3pez Mart\u00ednez MV, Pareja Rom\u00e1n J, Jim\u00e9nez Hern\u00e1ndez MD, Maestu Unturbe C, Ram\u00edrez-Castillejo MC (2020) Chronic migraine with medication overuse: clinical pattern and evolution from a retrospective cohort in Seville, Spain. SN Compr Clin Med 2:1514\u20131525","journal-title":"SN Compr Clin Med"},{"key":"1775_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s10194-016-0696-8","volume":"17","author":"K Thorlund","year":"2016","unstructured":"Thorlund K, Sun-Edelstein C, Druyts E, Kanters S, Ebrahim S, Bhambri R et al (2016) Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain 17:107","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01775-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01775-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01775-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T11:02:14Z","timestamp":1713870134000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01775-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01775-6","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}